Vectors for expression of prostate-associated antigens
AssigneePfizer Inc.
InventorJoseph John Binder
Life of this patent
Estimating the term…
Abstract
The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
Claims19
A method of treating prostate cancer in a human, which comprises administering to the human an effective amount of a C68 DNA vector, wherein the C68 DNA vector comprises:
- (1) a C68 nucleotide sequence;
- and (2) a multi-antigen construct, wherein the C68 nucleotide sequence is the sequence of SEQ ID NO:
- 57 lacking at least one gene selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 and L5 genes, wherein the multi-antigen construct encodes only two different immunogenic PAA polypeptides selected from the group consisting of:
- (1) an immunogenic PSMA polypeptide and an immunogenic PSA polypeptide;
- and
- (2) an immunogenic PSA polypeptide and an immunogenic PSCA polypeptide,
- wherein the two immunogenic PAA polypeptides are each encoded by a coding nucleotide sequence, and wherein the immunogenic PSA polypeptide consists of an amino acid sequence selected from the group consisting of:
- (1) an amino acid sequence consisting of amino acids 27-263 of SEQ ID NO:
- 15;
- and
- (2) the amino acid sequence of SEQ ID NO:17.
A method of treating prostate cancer in a human, which comprises administering to the human an effective amount of a pharmaceutical composition comprising a C68 vector and a pharmaceutically acceptable excipient, wherein the C68 vector comprises:
- (1) a C68 nucleotide sequence;
- and (2) a multi-antigen construct,
- wherein the C68 nucleotide sequence is the sequence of SEQ ID NO:
- 57 lacking at least one gene selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 and L5 genes, wherein the multi-antigen construct encodes only two different immunogenic PAA polypeptides selected from the group consisting of:
- (1) an immunogenic PSMA polypeptide and an immunogenic PSA polypeptide;
- and
- (2) an immunogenic PSA polypeptide and an immunogenic PSCA polypeptide, and
- wherein the immunogenic PSA polypeptide consists of the amino acid sequence of SEQ ID NO:17.
Dependencies are inferred from the claim text.